Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
This phase I trial studies the side effects and the best dose of Akt inhibitor MK2206 together with hydroxychloroquine in treating patients with advanced solid tumors, melanoma, prostate or kidney cancer. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving Akt inhibitor MK2206 together with hydroxychloroquine may kill more tumor cells.
Adult Solid Neoplasm
Hormone-Resistant Prostate Cancer
Recurrent Prostate Carcinoma
Recurrent Renal Cell Carcinoma
Stage IIIA Skin Melanoma
Stage IIIB Skin Melanoma
Stage IIIC Skin Melanoma
Stage IV Prostate Cancer
Stage IV Renal Cell Cancer
Stage IV Skin Melanoma
Drug: Akt Inhibitor MK2206
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
|Study Design:||Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis|
- Dose-limiting toxicity rate as assessed by CTCAE version 4.0 [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]
- MTD of Akt inhibitor MK-2206 as assessed by CTCAE version 4.0 [ Time Frame: 21 days ] [ Designated as safety issue: No ]
- Change in autophagy activity induced by hydroxychloroquine as measured by the amount of autophagosomes by EM [ Time Frame: Baseline to 4 weeks ] [ Designated as safety issue: No ]Student t-test and Wilcoxon nonparametric tests will be conducted.
- Changes in expression pattern of markers Beclin1, LC3, and p62 by immunohistochemistry (IHC), Western blotting, and number of autophagosomes by electron microscope (EM) [ Time Frame: Baseline to 4 weeks ] [ Designated as safety issue: No ]Spaghetti plots or boxplots at time points will be produced for each marker and for EM. Appropriate transformations of the measurements will be carried out to normalize the data. Descriptive summary statistics will be provided for each type of measure at each time point.
- Validation of Beclin1, LC3, and p62 as markers for autophagy measured by EM [ Time Frame: Up to 4 weeks ] [ Designated as safety issue: No ]Linear mixed models will be fitted to the data, EM as the independent variable, the 3 markers and time points as fixed effects, plus a subject-specific random effect. A backward variable selection will be carried out for the 3 markers until a final model is selected. An ROC curve will be produced. The log-transformed ratio of LC3-II/LC3-I and difference in the log-transformed ratios of LC3-II./LC3-I pre-post treatment between high autophagy activity (HA, >= 6 AV/cell) and low autophagy activity (LA, < 6 AV/cell) will be analyzed for evaluating treatment effect using a two sided paired t-test.
|Study Start Date:||November 2011|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Experimental: Treatment (Akt inhibitor MK2206, hydroxychloroquine)
Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15. Beginning on course 2, patients also receive hydroxychloroquine PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Drug: Akt Inhibitor MK2206
Other Names:Drug: Hydroxychloroquine
Other Name: HYDROXYCHLOROQUINEOther: Laboratory Biomarker Analysis
Correlative studiesOther: Pharmacological Study
I. To define the maximum tolerated dose (MTD) of MK-2206 (Akt inhibitor MK2206) and hydroxychloroquine (HCQ) when used in combination.
I. To determine side effects and activity of MK-2206 and hydroxychloroquine when used in combination.
II. To determine if hydroxychloroquine alters the pharmacokinetics of MK-2206 due to a drug-drug interaction.
III. To validate biomarkers for autophagy detection.
OUTLINE: This is a dose-escalation study of Akt inhibitor MK-2206.
Patients receive Akt inhibitor MK2206 orally (PO) on days 1, 8, and 15. Beginning on course 2, patients also receive hydroxychloroquine PO twice daily (BID) on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 4 weeks.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01480154
|United States, New Jersey|
|Rutgers Cancer Institute of New Jersey||Recruiting|
|New Brunswick, New Jersey, United States, 08903|
|Contact: Mark N. Stein 732-235-6031 email@example.com|
|Principal Investigator: Mark N. Stein|
|Principal Investigator:||Mark Stein||Rutgers Cancer Institute of New Jersey|